R DB PBO-CPts with IBS Rome II with bloatingVSL3a n  20 vs. PBO n  22 bid for 6 wkIBS mean symptom scores baseline vs. 6 wkVSL3IBS-SSS 224.5 vs. 158.0Abdominal pain intensity 18.8 vs. 15.0Abdominal pain duration 37.5 vs. 19 P  0.05Abdominal distension intensity 34.5 vs. 20 P  0.05QOL 63.8 vs. 52.5BM satisfaction 70.1 vs. 55.3Frequency of defecation 1.9 vs. 1.6Stool type 4.2 vs. 3.9VSL3 n  15 vs. PBO n  9 for 8 wkGSRS-IBS mean scores baseline vs. 8 wk VSL3bGlobal 2.8 vs. 1.5Pain 4.0 vs. 1.9Bloating 2.7 vs. 1.6Constipation 1.8 vs. 1.2Diarrhea 3.1 vs. 1.6Satiety 2.3 vs. 1.0VSL3 n  24 vs. PBO n  24 in yogurt for 4 or 8 wk - 1 wkc VAS mean symptom scores after 4 wk VSL3 vs. PBOBloating 32.4 vs. 38.1 P  0.19Pain 23.7 vs. 27.4 P  0.22Urgency 20.1 vs. 23.0 P  0.28Flatulence 30.8 vs. 40.1 P  0.01PBOIBS-SSS 226.4 vs. 183.5Abdominal pain intensity 27.7 vs. 21.8Abdominal pain duration 30.9 vs. 23.6Abdominal distension intensity 39.6 vs. 27.3QOL 59.6 vs. 50.2BM satisfaction 68.6 vs. 55.7Frequency of defecation 1.9 vs. 1.5Stool type 4.2 vs. 3.9PBOGlobal 2.4 vs. 1.7Pain 3.0 vs. 2.0Bloating 1.6 vs. 1.5Constipation 2.2 vs. 1.5Diarrhea 3.1 vs. 1.8Satiety 1.8 vs. 1.5Kim et al.

R DB PBO-CPts with IBS Rome II criteriaProbiotic milk-based drink Valio Ltd. Helsinki FinlandLactobacillus rhamnosus GG L rhamnosus Lc705 P freudenreichii ssp shermaniiJS and B animalis ssp lactis Bb121 1.2-dL drink daily containing 1 x 107 CFUsmL each probiotic strain for 20 wkProbiotic n  43 vs. PBO n  43 Primary end pointWeekly composite IBS symptom score including abdominal pain distension flatulence and rumbling decreased from baseline to wk 20 with probiotic and PBO 37 vs. 9 reduction respectively P  0.008Secondary end pointsDistension improved significantly with probiotic vs. PBO at wk 20 36 vs. 10 reduction P  0.02Abdominal pain decreased at wk 20 with probiotic but difference vs. PBO was not significant 38 vs. 0 P  0.052Flatulence and rumbling decreased in both groups at wk 20 but differ- ences between groups were not significant P  0.11 and P  0.09 respectivelyFrequency of soft stools 58 vs. 53 hard stools 16 vs. 15 and diarrhea 27 vs. 32 comparable between groups at wk 20AEs reported by 23.3 and 34.9 of pts receiving probiotic or PBO respectivelyAE adverse event bid twice daily BSS Bristol Stool Scale C controlled CFU colony-forming unit DB double-blind GI gastrointestinal HAD Hospital Anxiety and Depression IBS irritable bowel syndrome IBS-C irritable bowel syndrome with constipation IBS-D irritable bowel syndrome with diarrhea IBS-QOL irritable bowel syndrome quality of life IBS-SSS Irritable Bowel Syndrome-Symptom Severity Scale PBO placebo PBO-C placebo- controlled posttx posttreatment pts patients QOL quality of life R randomized SAE serious adverse event tx treatment VAS visual analog scale.aAssessed by 'yes' or 'no' response to the question 'Compared with your health before treatment started have overall IBS symptoms improved during the past 7 days'bWorst symptoms over previous 24 h on numeric scale ranging from 0 to 10.cChange in patient's bowel symptoms scored on a 7-point scale ranging from 'substantially worse' to 'substantially improved.

abdominal pain skin rash respectivelyNo AEs reported up to 60 wk follow upNot evaluatedOnly AE reported was mild diarrhea experienced by 6 pts 0.9AE adverse event bid twice daily C controlled CFU colony-forming unit DB double-blind IBS irritable bowel syndrome IBS-C constipation-predominant irritable bowel syndrome IBS-D diarrhea-predominant irritable bowel syndrome IBS-M mixedalternating irritable bowel syndrome MC multicenter NS not significant OL open-label PBO placebo PBO-C placebo-controlled pts patients R randomized tx treatment.100806040200Primary End PointAdequate Relief of Global IBS SymptomsKey Secondary End Point Adequate Relief of IBS-Related BloatingFigure 2.

patients with yes answer to the weekly satisfactory relief question for 4 of 8 weeklyassessments did not differ between groups 33 vs. 38 P  0.9GI transit no significant differences in gastric emptying after 2 and 4 h P  0.41 and P  0.86 respectively colonic filling after 6 h P  0.62 or colonic transit after 24 and 48 h P  0.70 and P  0.99 between groupsbid twice daily BM bowel movement DB double-blind GI gastrointestinal GSRS-IBS Gastrointestinal Symptom Rating Scale-irritable bowel syndrome IBS irritable bowel syndrome IBS-D irritable bowel syndrome with diarrhea IBS-SSS Irritable Bowel Syndrome-Symptom Severity Scale PBO placebo PBO-C placebo-controlled pts patients QOL quality of life R randomized VAS visual analog scale.aVSL Pharmaceuticals Inc. Gaithersburg MD USA.bP value for between-group differences for VSL3 vs. placebo were not significant.cDuration of treatment was amended from 8 wk to 4 wk after 17 patients completed 8 wk of treatment.Table 4.

Because of the substantial interest in the gut microbiota and its role in disease the purpose of this review is to provide an overview of specific interventions with the potential to modulate the gut microbiota in IBS including elimination diets prebiotics probiotics synbiotics and antibiotics.MethodsA PubMed search of English-language articles available through 24 August 2017 was conducted using the following key words to identify studies performed in adult humans 'irritable bowel syndrome AND diet' 'irritable bowel syndrome AND FODMAP' 'irritable bowel syndrome AND prebiotic' 'irri- table bowel syndrome AND probiotic' 'irritable bowel syn- drome AND Bifidobacterium' 'irritable bowel syndrome AND Lactobacillus' 'irritable bowel syndrome AND VSL 3' 'irritable bowel syndrome AND antibiotic' and 'irritable bowel syn- drome AND rifaximin.'

R DB PBO-CPts with IBS-DVAS mean symptom scores during entire treatment period VSL3 vs. PBO Bloating 31.3 vs. 38.5 P  0.11Pain 23.0 vs. 26.9 P  0.22Urgency 19.7 vs. 22.7 P  0.32Flatulence 29.7 vs. 39.5 P  0.01VSL3 n  12 vs. PBO n  13 bid for 8 wkPercentage of responders i.e.

R DB PBO-CPts with IBS Rome III criteriaLacClean Gold-S1 500-mg capsules 5 x 109 viable cells bid for 4 wkProbiotic vs. PBOPrimary end pointPts with global relief of IBS symptomsa after 4 wk 68.0 vs. 37.5 respectivelyP  0.03Secondary end pointsMean  decrease from baseline in intensity of abdominal paindiscomfort and bloatingb at wk 4 37.1 vs. 9.2 P  0.07 28.7 vs. 17.8 P  0.4 22.4 vs.20.3 P  0.9 respectively Change from baseline in mean number of weekly bowel movements at wk 4 -2.4 vs. 32.6 P  0.2 Change in stool consistency BSS at wk 4 0.5 vs. -3.3 P  0.7No AEs or SAEs in either groupKi Cha et al.

R DB PBO-CPts with non-constipation IBS functional diarrhea or functional bloating Rome IIILactobacillus acidophilus NCFM and Bifidobacterium animalis spp lactis Bi-07 1 pill containing 1 x 1011 CFUs bid for 8 wkProbiotic n  31 vs. PBO n  29 Primary end pointsGlobal relief of GI symptomsc and satisfaction with treatmentd improved from baseline in both groups but did not differ significantly between groupsSecondary end pointsAbdominal pain improved from baseline to wk 8 probiotic 3.3 vs. 2.5P  0.03 PBO 3.7 vs. 2.5 P  0.01 but did not differ significantly between groupsBloating improved significantly at wk 4 vs. PBO score at wk 4 4.1 vs. 6.2P  0.009 and numerically at week 8 score at wk 8 4.3 vs. 5.8 P  0.06IBS-QOL improved from baseline in both groups but did not differ sig- nificantly between groupsNo differences in AEs between groupsAEs included cold symptoms fatigue abdominal pain and sinus infectionSimren et al.

synbiotic 550 mg every 2-3 d n  6 3 episodic tx synbiotic use when mild IBS symptoms perceived to occur n  10Follow-up phase up to 60 wkSynbiotic Prescript-Assist 500 mg bid n  12 vs. PBO n  13 for 2 wkZir Fosr Alfa Wasserman Alanno Scalo Pescara ItalyBifidobacterium longum W11 probiotic Fos Actilightprebiotic 3 g daily for 36 dSynbiotic vs. prebioticPercentage of pts with no or mild pain wk 4 54 vs. 57.4 respectively wk 8 60.9 vs. 53.9 wk 12 53.9 vs. 53.4 P  NS for all comparisonsPercentage of pts with self-reported improvement in well- being wk 4 60.7 vs. 61.7 respectively wk 8 69.2vs.

R DB PBO-CPts with IBS Rome IIILactobacillus acidophilus 5 x 109 CFUs L reuteri 5 x 109 CFUs or 2 L plantarum 5 x 109 CFUs L rhamnosus 5 x 109 CFUs Bifidobacterium animalis ssp lactis 5 x 109 CFUsCapsules administered once daily for 60 dLacClean Gold-S Cell Biotech Co. Ltd. Gimpo KoreaBifidobacterium bifidum B lactis B longum Lactobacillus acidophilus L rhamnosus and Streptococcus thermophilus2 500-mg capsules 5 x 109 viable cells per capsule daily for 4 wkProbiotic 1 and 2 vs. PBOResponse decrease from baseline 30 in symptoms for 50 of time for 60 d 1 66-78 and 2 78-90 vs. PBO 6-36 P  0.001Response during 30-d follow period 1 56-74 and 2 76-82 vs. PBO 10-40 P  0.001Probiotic vs. PBOOverall adequate symptom relief 74.4 vs. 61.9 of patients respectivelyP  0.2Mean change from baseline in IBS symptoms VAS scores at wk 4Paindiscomfort P  0.4Bloatinggas P  0.5Constipation P  0.9Diarrhea P  0.02Not examinedNot examinedYoon et al.

